Tag: AASLD
Inventiva announces a late breaker abstract and two additional abstracts on its lead drug candidate, lanifibranor, at the Liver Meeting™ 2023 organized by the AASLD – 11/06/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), November 6, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Poxel Presents Phase II (DESTINY-1) Results of PXL065 for the Treatment of NASH at AASLD The Liver Meeting® 2022 – 11/07/2022 8:15 PM
– “Late-breaking abstract” selected by the AASLD as one of the best of the 2022 edition (“Best of the Liver Meeting”) – The phase II study of PXL065 for the…
Inventiva: abstract planned at the AASLD conference
(CercleFinance.com) – Inventiva announces the selection of a scientific abstract for The Liver Meeting 2022 conference, organized by the AASLD from November 4 to 8 in Washington, which assesses the…
Inventiva: abstract planned at the AASLD conference – 2022-10-24 at 07:43
(CercleFinance.com) – Inventiva announces the selection of a scientific abstract for The Liver Meeting 2022 conference, organized by the AASLD from November 4 to 8 in Washington, which assesses the…
Inventiva announces the presentation of a scientific abstract during The Liver Meeting™ 2022 organized by AASLD – 2022-10-21 at 22:00
Daix (France), Long Island City (New York, United States), October 21, 2021 Daix (France) – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of…